The Lancet: Smoking cessation medications do not appear to increase risk of neuropsychiatric side effects, study finds
(The Lancet) The smoking cessation medications varenicline and bupropion do not appear to increase the incidence of serious neuropsychiatric side effects compared to placebo, according to a study published in The Lancet today. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 22, 2016 Category: Global & Universal Source Type: news
Anti-smoking drug may also help combat sugar cravings
Conclusion
This animal research provides evidence that, as expected, the chemical reward pathways within brain – involving a region called the nucleus accumbens – are involved when excessive amounts of sugar are consumed on a regular basis. This is similar to that involved with substance addiction, such as nicotine. The researchers subsequently found evidence that the smoking cessation drug varenicline can reduce sugar consumption when injected into rats.
However, it is difficult to draw many further implications from the research at this stage. For one thing, we don't really know what type of dietary intake in humans...
Source: NHS News Feed - April 11, 2016 Category: Consumer Health News Tags: Food/diet Medication Source Type: news
Chantix: Quarterwatch Article
In 2006, the Pfizer product, Chantix (varenicline), was FDA-approved as a smoking cessation aid. Soon after marketing, FDA became aware through its postmarketing surveillance system, the Adverse Events Reporting System or AERS, of the potential for serious neuropsychiatric events in patients taking Chantix. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 11, 2016 Category: Drugs & Pharmacology Source Type: news
FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease
6-16-2011] The U.S. Food and Drug Administration (FDA) is notifying the public that the smoking cessation aid Chantix (varenicline) may be associated with a small, increased risk of certain cardiovascular adverse events in patients who have cardiovascular disease. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 2, 2016 Category: Drugs & Pharmacology Source Type: news
Comunicado de la FDA sobre la seguridad de los medicamentos: La etiqueta del medicamento Chantix (vareniclina) ahora contiene información actualizada sobre su eficacia y seguridad
El 22 de julio de 2011,la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA por sus siglas en inglés) ha aprobado la actualización de la etiqueta del medicamento para dejar de fumar Chantix (vareniclina), la cual ahora incluye información sobre la eficacia y seguridad del medicamento para dos grupos de pacientes que pueden beneficiarse mucho si dejaran de fumar: aquellos con enfermedades cardiovasculares y aquellos con una enfermedad pulmonar obstructiva crónica (EPOC). La etiqueta actualizada ahora incluye instrucciones alternativas para que los pacientes decidan la fecha en la que dejarán de fum...
Source: FDA Center for Drug Evaluation and Research - What's New - March 1, 2016 Category: Drugs & Pharmacology Source Type: news
Study: Nicotine Patch Works as Well as Chantix to Help Quit Smoking
This study confirms that FDA-approved medications are effective in helping smokers quit,” said Lee Westmaas, PhD, American Cancer Society director of tobacco control research. “Smokers should seriously consider using medications if they are finding it difficult to quit without any help. The most effective approach to quitting is using medications in combination with counseling such as from a quit-line.”RESOURCES: How to Quit Smoking Quit-smoking medicationsResearch shows that using a medication to help you quit smoking can double your chances of being successful.The US Food and Drug Administr...
Source: American Cancer Society :: News and Features - February 2, 2016 Category: Cancer & Oncology Tags: Smoking/Tobacco Source Type: news
No Efficacy Difference for Chantix, Nicotine Replacement (CME/CE)
(MedPage Today) -- Smoking cessation treatments equally effective in randomized trial (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - January 27, 2016 Category: Respiratory Medicine Source Type: news
No Clear Winner Seen Among Stop-Smoking Aids
Whether you use the nicotine patch, lozenges or Chantix, strong desire to quit is key, experts say (Source: WebMD Health)
Source: WebMD Health - January 26, 2016 Category: Consumer Health News Source Type: news
No Winners in Patch/Lozenge Combo Study
(MedPage Today) -- Combo, Varenicline tie for helping smokers quit (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 26, 2016 Category: Primary Care Source Type: news
No Clear Winner Seen Among Stop-Smoking Aids in Study
Whether you use the nicotine patch, lozenges or Chantix, strong desire to quit is key, experts say
Source: HealthDay
Related MedlinePlus Page: Quitting Smoking (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - January 26, 2016 Category: Consumer Health News Source Type: news
Medical News Today: Smoking cessation therapies 'have limited effect'
Nicotine patches, varenicline or a combination of the two are used to help people quit smoking, but findings question whether they are really worth the cost, time and trouble. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 26, 2016 Category: Consumer Health News Tags: Smoking / Quit Smoking Source Type: news
Effects of Varenicline on alcohol enjoyment and consumption
Conclusion
Varenicline may affect enjoyment of drinking, but its potential to alter drinking behaviour is likely to be small.
Further Information
Conflicts of interest
PH and HM have received research funds and/or consultancy fees from manufacturers of smoking cessation medications. The remaining authors have no conflicts of interest to declare.
References
Childs, E., Roche, D. J. O., King, A. C. & De Wit, H. (2012). Varenicline Potentiates Alcohol-Induced Negative Subjective Responses and Offsets Impaired Eye Movements. Alcoholism: Clinical and Experimental Research, 36, 906-914.
Davis, T. J. & De Fiebre, C. M. (...
Source: Alcohol Research UK - December 16, 2015 Category: Addiction Authors: admin Tags: Alcohol Insights Source Type: news
New ACS Cocktail: ASA, Antiplatelets, Beta-blockers, and Now Varenicline? New ACS Cocktail: ASA, Antiplatelets, Beta-blockers, and Now Varenicline?
Dr Melissa Walton-Shirley reports on the impressive results of the EVITA varenicline trial in the highest-risk population possible: MI patients in the hospital. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 10, 2015 Category: Cardiology Tags: Cardiology Expert Column Source Type: news
Varenicline Started in ACS Hospitalization Helps Smokers QuitVarenicline Started in ACS Hospitalization Helps Smokers Quit
In a randomized trial, a rare successful showing for a smoking-cessation medication in this particularly sick population, abstinence at 24 weeks was confirmed by carbon-monoxide breath analysis. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 9, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Anti-Smoking Drug Chantix May Help Women Sooner Than Men
Title: Anti-Smoking Drug Chantix May Help Women Sooner Than MenCategory: Health NewsCreated: 10/13/2015 12:00:00 AMLast Editorial Review: 10/14/2015 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - October 14, 2015 Category: Respiratory Medicine Source Type: news
